JR Pharma Engineering ApS: Financial statements 2025
CVR: 42398993
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
JR Pharma Engineering ApS (CVR 42398993) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 1,925,862 and a net result of DKK 591,630 compared with DKK 650,721 the year before. That is a decrease of 1.7% compared with the year before. The profit margin was 30.7%. Equity in the 2025 report amounted to DKK 633,571. The solvency ratio was 63.4%.
- Revenue
- DKK 1,925,862
- Gross Profit
- DKK 1,908,042
- Profit/Loss
- DKK 591,630
- Equity
- DKK 633,571
- Total Assets
- DKK 998,610
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 1.9 mio. | 1.9 mio. | 592 t. | 634 t. | - |
| 2024 | 2 mio. | 1.9 mio. | 651 t. | 693 t. | - |
| 2023 | 1.9 mio. | 1.8 mio. | 645 t. | 687 t. | - |
Official annual report
How creditworthy is JR Pharma Engineering ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout JR Pharma Engineering ApS
JR Pharma Engineering ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2021. The company is registered under the industry Rådgivende ingeniøraktiviteter inden for byggeri og anlægsarbejder. The management consists of Jimmy Rønne Jensen. The company is owned by JR Pharma Engineering Holding ApS. In 2026, the company reported revenue of DKK 2,000,220 and a net result of DKK 432,091 compared with DKK 591,630 the year before. Equity in the 2026 report amounted to DKK 474,033.